Point72 Asset Management L.P. Takes Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Point72 Asset Management L.P. purchased a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 359,796 shares of the company's stock, valued at approximately $41,114,000. Point72 Asset Management L.P. owned approximately 0.29% of Vaxcyte as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Blue Trust Inc. boosted its holdings in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after acquiring an additional 93 shares during the period. Nisa Investment Advisors LLC grew its stake in Vaxcyte by 5.2% during the third quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company's stock worth $252,000 after buying an additional 110 shares during the last quarter. CIBC Asset Management Inc grew its stake in Vaxcyte by 3.6% during the third quarter. CIBC Asset Management Inc now owns 3,136 shares of the company's stock worth $358,000 after buying an additional 110 shares during the last quarter. Amalgamated Bank grew its stake in shares of Vaxcyte by 4.2% during the second quarter. Amalgamated Bank now owns 3,759 shares of the company's stock valued at $284,000 after purchasing an additional 150 shares during the last quarter. Finally, Riverview Trust Co bought a new stake in shares of Vaxcyte during the third quarter valued at approximately $27,000. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Stock Down 3.2 %

Shares of NASDAQ:PCVX traded down $3.00 during midday trading on Thursday, hitting $90.04. The stock had a trading volume of 1,154,102 shares, compared to its average volume of 907,190. The company's 50-day moving average price is $103.85 and its 200-day moving average price is $90.72. The company has a market capitalization of $11.22 billion, a P/E ratio of -19.57 and a beta of 0.94. Vaxcyte, Inc. has a fifty-two week low of $53.41 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same quarter last year, the firm earned ($0.91) EPS. Research analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Insider Buying and Selling

In other Vaxcyte news, SVP Mikhail Eydelman sold 5,000 shares of the business's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $109.27, for a total transaction of $546,350.00. Following the sale, the senior vice president now directly owns 28,623 shares of the company's stock, valued at $3,127,635.21. The trade was a 14.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Grant Pickering sold 15,000 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the sale, the chief executive officer now directly owns 450,301 shares in the company, valued at $41,630,327.45. The trade was a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,464 shares of company stock worth $11,924,596 in the last three months. 3.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Mizuho raised their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Bank of America lifted their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Jefferies Financial Group lifted their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.